design: we conducted a prospective study in 1294 men with prostate cancer, without recurrence or progression as of 2004â€“2005, who were participating in the cancer of the prostate strategic urologic research endeavor and who were followed for an average of 2 y. results: we observed 127 events (prostate cancer death or metastases, elevated prostate-specific antigen concentration, or secondary treatment) during 2610 person-years.